Evaluate

April 03, 2018

First-quarter acquisition activity lifts hopes for a big year

After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.

January 31, 2018

Bellicum’s cells not so controllable after all

January 24, 2018

Tmunity parks its tanks on Novartis’s lawn

January 23, 2018

Biotech gets creative about the pay cheque

Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.

January 22, 2018

Sanofi bets against haemophilia gene therapy

January 22, 2018

Juno falls to Celgene

January 17, 2018

Juno jumps but is Celgene a worthy worshipper?

January 16, 2018

Blockbuster approvals line up for biopharma in 2018

2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.

January 12, 2018

JP Morgan interview – Crispr hopes its CAR will overtake Cellectis